# Replimune Group Inc. (REPL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.04, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Replimune Group Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 12.0×**. The shares trade at 12.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -19.8%** (5-yr avg -24.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -188.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -10.1%**. Earnings per share fell 10.1%.

## Financial health
- **Debt to equity: 0.50**. Debt is 0.50 times equity, moderate leverage.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Replimune Group Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (6 analysts). 6 analysts cover Replimune Group Inc.; the consensus is buy, with an average price target of $19.50 (+30% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 158.9%** (YTD 54.7%, 3-mo 58.8%). The shares are up 158.9% over twelve months including dividends.
- **From 52-week high: -7.9%** (902.7% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.14** (volatility 217%). Beta of 1.14 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=REPL · Page: https://foliofundamentals.com/stocks/repl

Not investment advice.